Drug Topics

JANUARY 1, 2025

Check out this list of our top 5 most read immunization stories from the year 2024.

Immunization 247

Immunization 247

Med Ed 101

JANUARY 1, 2025

I’ve compiled this YouTube video to help candidates best prepare for their 2025 BCPS pharmacy exam. Pass rates continue to be in the 60% range so it is difficult to pass this exam. There are significant changes this year in the 2025 BCPS Exam compared to last spring. The content outline has shifted significantly. Here […] The post 2025 BCPS Pharmacy Exam – What You Need To Know appeared first on Med Ed 101.

105

105

Pharmacy Times

JANUARY 1, 2025

Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.

139

139

Fierce Healthcare

JANUARY 1, 2025

Hospitals and health systems, by and large, are going into 2025 on better footing than a year ago, as financial and operating performance stabilized. | Hospitals and health systems, by and large, are going into 2025 on better footing than a year ago, as financial and operating performance stabilized.

Hospitals 130

Hospitals 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JANUARY 1, 2025

Some outsourcers and pharmacies have capitalized on the shortages, producing compounded versions.

Compounding 132

Compounding FDA 132

Pharmaceutical Commerce

JANUARY 1, 2025

This bucket of Pharma Commerce coverage is highly powered by digital solutions.

52

52

PharmExec

JANUARY 1, 2025

In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), speaks about exciting developments in fertility treatment that he anticipates in the next few years.

52

52

Pharmacy Times

JANUARY 1, 2025

Female adolescents were at an increased risk of experiencing depression and anxiety symptoms compared with males.

111

111

PharmExec

JANUARY 1, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmacy Times

JANUARY 1, 2025

Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.

65

65

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The FDA Law Blog

JANUARY 1, 2025

By Sara W. Koblitz Since the induced infringement finding in GSK v. Teva , the generic industry has feared the death of the skinny label (admittedly stoked by alarmist headlines like my own, see Ding Dong is the Skinny Label (Effectively) Dead? ). This is because, at a minimum, if a skinny-labeled generic is the basis for induced infringement liability, generic manufacturers will certainly think twice about using the skinny label process and still calling themselves AB-rated, which ultimately w

Labelling 105

Labelling FDA 105

Pharmacy Times

JANUARY 1, 2025

Panelists discuss how seladelpar showed remarkable efficacy in the RESPONSE trial, demonstrating significant improvements in alkaline phosphatase levels and other biochemical markers compared with placebo.

65

65

OctariusRx

JANUARY 1, 2025

Happy New Year ! As we stand on the cusp of a new year, lets take a moment to give thanks and look forward to a brand-new chapter. We hope 2024 was a great year for everyone and that 2025 holds success and good fortune in all endeavors you pursue. 2024 was an incredible year for the OctariusRx team and we owe it all to our clients, family, and friends.

91

91